Vonoprazan
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Trial Timeline
May 15, 2025 → Sep 1, 2034
NCT ID
NCT06660342About Vonoprazan
Vonoprazan is a pre-clinical stage product being developed by Phathom Pharmaceuticals for Erosive Esophagitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06660342. Target conditions include Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease.
What happened to similar drugs?
6 of 13 similar drugs in Erosive Esophagitis were approved
Approved (6) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
3
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06660342 | Pre-clinical | Recruiting |
| NCT06391177 | Phase 1 | Completed |
| NCT06106022 | Phase 1 | Completed |
| NCT05343364 | Phase 1 | Completed |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 35 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 40 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 40 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 43 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 35 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 43 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 47 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| AZD0865 | AstraZeneca | Phase 2 | 35 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 43 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 43 |
| AZD0865 | AstraZeneca | Phase 2 | 35 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 43 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 35 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 37 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 23 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 34 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 29 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 34 |